临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1441674-54-9

Ledipasvir acetone

中文名称:雷迪帕韦单丙酮溶剂化物
CAS号:1441674-54-9
分子式: C52H60F2N8O7 分子量: 947.08
产品形式: Free Base
研发状态: Completed
研发用途: Hepatitis C Chronic; Hematologic Malignancy
研究机构: Ain Shams University; Cairo University
研发日期: March 1 2019
研发阶段: Phase 1 : Phase 2
Ledipasvir (GS-5885) acetone is the active ingredient of Ledipasvir. Ledipasvir is a potent, oral active inhibitor of the hepatitis C virus (HCV) NS5A with EC50 of 31 pM and 4 pM against GT1a and GT1b replicon, respectively.

CAS: 144143-96-4

Eprosartan Mesylate

中文名称:甲磺酸依普罗沙坦
CAS号:144143-96-4
分子式: C23H24N2O4S.CH4O3S 分子量: 520.62
产品形式: Mesylate
研发状态: Completed
研发用途: Hypertension; Stroke
研究机构: Abbott
研发日期: Mar-12
研发阶段: --
Eprosartan(SKF-108566J) is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.

CAS: 1440964-89-5

Bozitinib (PLB-1001)

中文名称:伯瑞替尼
CAS号:1440964-89-5
分子式: C20H15F3N8 分子量: 424.38
产品形式: free base
研发状态: Recruiting
研发用途: Metastatic Non Small Cell Lung Cancer
研究机构: Washington University School of Medicine; Apollomics Inc.
研发日期: January 18 2022
研发阶段: Phase 1 : Phase 2
Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.

CAS: 144060-53-7

Febuxostat

中文名称:非布索坦
CAS号:144060-53-7
分子式: C16H16N2O3S 分子量: 316.37
产品形式: free base
研发状态: Not yet recruiting
研发用途: Gout
研究机构: University Hospital Rouen
研发日期: January 1 2022
研发阶段: Phase 3
Febuxostat (TMX 67, TEI-6720) is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

CAS: 14402-89-2

Sodium nitroprusside

中文名称:硝普酸钠
CAS号:14402-89-2
分子式: C5FeN6O2Na 分子量: 261.92
产品形式: Sodium
研发状态: Not yet recruiting
研发用途: Lynch Syndrome; Recurrent Uterine Corpus Carcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer
研究机构: Gynecologic Oncology Group; National Cancer Institute (NCI); GOG Foundation
研发日期: Jan-00
研发阶段: --
Sodium nitroprusside (SNP, Ro 21-2498) is a generically available and rapid-acting intravenous (IV) vasodilator that dilates cerebral vessels and increases internal carotid (ICA) flow.

CAS: 1439399-58-2

Telaglenastat (CB-839)

中文名称:KGA和GAC抑制剂(CB-839)
CAS号:1439399-58-2
分子式: C26H24F3N7O3S 分子量: 571.57
产品形式: free base
研发状态: Recruiting
研发用途: Leptomeningeal Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
研究机构: National Cancer Institute (NCI)
研发日期: October 26 2020
研发阶段: Phase 1
Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.